Clinical Evaluation of Drug–Drug Interactions With Aficamten
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2026-03-01
|
| Серія: | Clinical and Translational Science |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1111/cts.70514 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|